A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer.

CONCLUSION: For patients without development of IRRs upon the first ramucirumab administration, shortening infusion time (from 60 to 20 minutes) is safe and feasible.
PMID: 30305415 [PubMed - as supplied by publisher]

Source: The Oncologist - October 10, 2018 Category: Cancer & Oncology Authors: Hashimoto N, Mitani S, Taniguchi H, Narita Y, Kato K, Masuishi T, Kadowaki S, Onishi S, Tajika M, Takahashi S, Shimomura K, Takahata C, Hotta E, Kobara M, Muro K Tags: Oncologist Source Type: research